🧠This Week in Immunology: Pediatric Rheum Funding, Crohn’s Advances, Global Biotech Deals, Regulatory Shifts and More
Stay up to date with the latest in immunology—from expanded pediatric research funding and breakthrough biologics to global acquisitions and regulatory milestones in autoimmune and inflammatory disease care:
đź’° $2M in Pediatric Rheumatology Grants Awarded by CARRA and the Arthritis Foundation to support research in JIA, lupus, dermatomyositis, and kidney disease. Includes 13 new awards to close gaps in care and accelerate outcomes for children.
🧬 Mirikizumab Approved by NICE for Crohn’s disease patients unresponsive to previous biologics. Backed by Phase 3 data showing 45 percent remission vs. 20 percent for placebo after one year.
🤝 Zentiva and Lupin Partner on Certolizumab Pegol to treat arthritis, Crohn’s disease, and plaque psoriasis—starting with a $10M upfront and up to $50M in milestones. Zentiva leads Europe/CIS; Lupin oversees the U.S. and global expansion.
đź’Š Deuruxolitinib (Leqselvi) Launches in the U.S. for severe alopecia areata. Long-term trial data show nearly 50 percent achieved SALT scores of 20 or less by week 68. Includes financial access programs via Sun Pharma.
🏥 Epiphany Dermatology Expands in Missouri, acquiring Associates in Dermatology & Cutaneous Surgery to boost care access, clinical talent, and infrastructure in St. Louis.
🌍 Leo Pharma Acquires Spevigo from Boehringer Ingelheim for €90M. Already approved for generalized pustular psoriasis, Spevigo is also under trial for pyoderma gangrenosum—bolstering Leo’s rare disease pipeline.
🇯🇵 Otsuka Acquires CAN10 from Cantargia for $33M upfront and up to $580M in milestone payments. CAN10 targets IL-1 cytokines in autoimmune diseases and includes backup compounds.
🧪 FDA Grants Orphan Drug Designation to STEAP1 ADC ADRX-0405 for gastric cancer. Currently in Phase 1 for advanced solid tumors with 7-year exclusivity and tax credits under the designation.
🇰🇷 Astellas Reapplies for Vyloy Reimbursement in Korea, the world’s first Claudin 18.2-targeted gastric cancer therapy. Already approved in 13 countries and recognized as a first-line standard of care globally.
📢 Stay Ahead in Immunology Research!
âś… Like, share, and subscribe for weekly updates on immunology and autoimmune innovation
#Immunology #CrohnsDisease #PediatricRheumatology #AlopeciaAreata #DermatologyNews #BiotechDeals #Certolizumab #CAN10 #OrphanDrugs #AutoimmuneInnovation #LeoPharma #SunPharma #LucidQuest #ClinicalResearch #DrugDevelopment #Vyloy #Claudin18_2
Â